Heteroaryl benzene compound

Heteroarylbenzene compounds represented by the general formula (1): (1) [wherein A is N or CH; R1 is hydrogen or C1-8 alkyl; R2a and R2b may be the same or different and are each a group selected from the group consisting of hydrogen, halogeno, and C1-6 alkyl: Q is substituted or unsubstituted phenyl, benzyl, naphthyl, tetrahydronaphthyl, C3-10 cycloalkyl, or the like; m is 0 or 1; n is 0 or 1; X is -O- or -NR3-; and Y is substituted or unsubstituted C1-8 alkylene or the like]; tautomers, stereoisomers or pharmaceutically acceptable salts of the compounds; or solvates of the same are useful as drugs for the prevention or treatment of diseases or symptoms which can be ameliorated by the inhibition of DGAT1, for example, obesity, hyperlipemia, hypertriglyceridemia, lipometabolic disorder, diabetes, arteriosclerosis; or obesity-caused, hyperlipemia, hypertriglyceridemia, lipometabolic disorder, diabetes, arteriosclerosis or hypertension.